


Claims

1. An organ preservative which is characterized in comprising a MAPK inhibitor and/or an inhibitor on the production of interleukin-1 (IL-1) and/or an inhibitor on the production of tumor necrosis factor (TNF) as effective ingredient(s).
2. An organ preservative of claim 1, wherein the MAPK inhibitor is a p38 MAPK inhibitor, the inhibitor on the production of interleukin-1 (IL-1) is an inhibitor on the production of interleukin-1 β (IL-1 β) and the inhibitor on the production of tumor necrosis factor (TNF) is an inhibitor on the production of tumor necrosis factor- α (TNF- α).
3. An organ preservative of claim 1 or 2, wherein the MAPK inhibitor and/or the inhibitor on the production of interleukin-1 (IL-1) and/or the inhibitor on the production of tumor necrosis factor (TNF) is/are a compound represented by the formula:

20




[wherein, R¹ is hydrogen, lower alkyl or acyl, R² is hydrogen or acyl, R³ is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), and R⁴ is heterocyclic group which may have suitable substituent(s),


25

heterocyclic (lower) alkyl, heterocyclic thio or heterocyclic sulfinyl] or a salt thereof.


4. An organ preservative of claim 1 or 2, wherein the MAPK inhibitor and/or the inhibitor on the production of
 5 interleukin-1 (IL-1) and/or the inhibitor on the production of tumor necrosis factor (TNF) is/are a compound represented by the formula:



- [wherein, R¹ is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R² is aryl which may have suitable substituent(s) or a
 15 heterocyclic group which may have suitable substituent(s), and Y a bivalent radical selected from




and




- 25 (in which ----- is a single bond or a double bond), each of

which may have suitable substituent(s)] or a salt thereof.

5. An organ preservative of claim 1 or 2, wherein a MAPK inhibitor and/or an inhibitor on the production of interleukin-1 (IL-1) and/or the inhibitor on the production of tumor necrosis factor (TNF) is/are a compound represented by the formula:



10 [wherein, R¹ is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R² is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R³ is hydrogen or acyl, R⁴ is hydrogen, lower alkyl, cyclo (lower) alkyl, cyclo (lower) alkyl-(lower) alkyl, carboxy (lower) alkyl, protected carboxy (lower) alkyl, ar (lower) alkyl which may have suitable substituent(s), ar (lower) alkenyl, bridged tricyclic alkyl, heterocyclic group which may have suitable substituent(s), acyl or a group of the formula



(where A is lower alkylene), and R⁵ is hydrogen or lower alkyl] or a salt thereof.

6. An organ preservative of claim 5, which is
7-(4-fluorophenyl)-2-phenylglyoxyloyl-8-(pyridin-4-yl)-
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine , or a salt
thereof.

5